GO:0004992 platelet activating factor receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004992 (platelet activating factor receptor activity) is a molecular function defined as combining with platelet activating factor (PAF) to initiate a change in cell activity.
• The PAF receptor (PTAFR) is a G-protein-coupled receptor that mediates diverse cellular responses including inflammation, chemotaxis, and gene regulation.
• PAFR signaling contributes to pathologies such as colitis-induced liver inflammation, demyelination, cancer progression, and retinal progenitor regulation.
• PAF can also exert receptor-independent effects, as shown in lysophosphatidylcholine-induced demyelination models.
• Targeting PAFR with antagonists or genetic tools is an active area of therapeutic research in cancer and inflammatory diseases.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of PAFR function in disease contexts.
Description
Platelet activating factor (PAF) is a potent phospholipid mediator with pleiotropic biological actions. Its cellular effects are largely transduced through the platelet activating factor receptor (PAFR), a G-protein-coupled receptor encoded by the PTAFR gene. The molecular function defined by GO:0004992, platelet activating factor receptor activity, captures the ability of a receptor to bind PAF and initiate a change in cell activity. This function is central to inflammatory signaling, vascular biology, and neural development, and its dysregulation has been implicated in a wide range of diseases. Understanding PAFR activity at the molecular level is therefore essential for both basic biology and therapeutic development. Researchers have employed genetic and pharmacological approaches to study PAFR, including receptor antagonists and knockout models. Recent studies have expanded the known roles of PAFR into areas such as retinal progenitor/stem cell regulation and cancer microvesicle release. This article synthesizes current knowledge on the mechanism, genes, and research methods associated with GO:0004992, based on authoritative QuickGO data and verified PubMed literature.
platelet activating factor receptor activity At A Glance
| GO ID | GO:0004992 |
|---|---|
| GO term | platelet activating factor receptor activity |
| Ontology | molecular_function |
| Synonym | PAF receptor activity |
| Definition | Combining with platelet activating factor to initiate a change in cell activity. |
| Major function | Binding of PAF and initiation of intracellular signaling. |
| Representative gene | PTAFR (platelet activating factor receptor) |
| Associated processes | Inflammation, chemotaxis, immune regulation, neural development. |
| Disease relevance | Colitis, liver inflammation, demyelination, cancer, retinal disorders. |
What Is GO:0004992?
Platelet activating factor receptor activity (GO:0004992) is a molecular function that describes the binding of platelet activating factor (PAF) to a receptor, which then triggers intracellular signaling events leading to a change in cell behavior. This activity is typically mediated by the PAF receptor (PAFR), a seven-transmembrane G-protein-coupled receptor that couples to G-proteins and activates downstream pathways.
Why Is platelet activating factor receptor activity Important in Cell Biology?
Platelet activating factor receptor activity is a key molecular function in inflammatory and immune responses, and its dysregulation contributes to multiple human diseases. Understanding this activity provides insights into both physiological processes and pathological mechanisms, and it offers a target for therapeutic intervention.
• Mediates the biological actions of PAF, a potent lipid mediator.
• Plays a central role in inflammation and immune cell recruitment.
• Contributes to colitis-induced liver inflammation.
• Influences demyelination and neural repair processes.
• Regulates retinal progenitor/stem cell profile.
• Is implicated in cancer progression and therapy response.
• Serves as a target for receptor antagonists in drug development.
• Provides a model for studying GPCR signaling and regulation.
• Enables research on receptor-dependent vs. independent effects of PAF.
• Supports development of CRISPR-based disease models.
Molecular Mechanism of platelet activating factor receptor activity
PAF Binding and Receptor Activation
In simple terms: PAF binds to its receptor like a key in a lock, turning the receptor on.
The platelet activating factor receptor (PAFR) is a G-protein-coupled receptor that specifically binds PAF. Upon binding, the receptor undergoes conformational changes that activate associated heterotrimeric G-proteins, leading to downstream signaling.
G-Protein Coupling and Second Messenger Generation
In simple terms: Once activated, the receptor triggers a chain reaction inside the cell.
Activated PAFR couples to G-proteins, which can stimulate phospholipase C, leading to production of inositol trisphosphate and diacylglycerol, and mobilization of intracellular calcium. These second messengers propagate the signal to various effectors.
Downstream Signaling Pathways
In simple terms: The signal spreads to control many cell functions.
PAFR signaling activates multiple pathways including MAPK, PI3K/Akt, and NF-kB, which regulate gene expression, cell survival, and inflammatory responses. These pathways mediate effects such as cytokine production and cell migration.
Receptor Regulation and Desensitization
In simple terms: The receptor can be turned off to prevent overstimulation.
Like many GPCRs, PAFR undergoes phosphorylation and internalization upon prolonged stimulation, leading to desensitization. This regulation is critical for maintaining appropriate cellular responses.
Receptor-Independent Effects of PAF
In simple terms: Sometimes PAF can act without its receptor.
Studies have shown that PAF can exert receptor-independent effects, as demonstrated in lysophosphatidylcholine-induced demyelination where both receptor-dependent and -independent mechanisms contribute to pathology.
Key Genes Involved in GO:0004992 platelet activating factor receptor activity
The following genes and proteins are directly or indirectly involved in platelet activating factor receptor activity and its signaling network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTAFR | Encodes the platelet activating factor receptor, a GPCR that binds PAF. | Central to GO:0004992; target for knockout and pharmacological studies. |
| GNAQ | G-protein alpha subunit that couples to PAFR. | Mediates downstream signaling from PAFR. |
| GNAI1 | G-protein alpha inhibitory subunit. | Modulates PAFR signaling. |
| PLCB1 | Phospholipase C beta 1, generates IP3 and DAG. | Key effector of PAFR-induced calcium signaling. |
| MAPK1 | Mitogen-activated protein kinase 1. | Transduces PAFR signals to gene expression. |
| AKT1 | Serine/threonine kinase involved in survival. | Downstream of PAFR in cancer and inflammation. |
| NFKB1 | Nuclear factor kappa B subunit 1. | Mediates inflammatory gene expression downstream of PAFR. |
| PTGS2 | Cyclooxygenase-2, involved in prostaglandin synthesis. | Induced by PAFR signaling in inflammation. |
| IL6 | Interleukin 6, pro-inflammatory cytokine. | Upregulated by PAFR activation. |
| TNF | Tumor necrosis factor, pro-inflammatory cytokine. | Contributes to PAFR-mediated inflammation. |
| CXCL8 | Interleukin 8, neutrophil chemoattractant. | Secreted upon PAFR activation. |
| CCL2 | Monocyte chemoattractant protein-1. | Induced by PAFR in inflammatory models. |
| RPE65 | Retinal pigment epithelium-specific protein. | Related to retinal progenitor regulation by PAFR. |
| SOX2 | Transcription factor in stem cells. | Modulated by PAFR in retinal progenitor cells. |
| CD44 | Cell-surface glycoprotein. | Involved in PAFR-mediated microvesicle release. |
| ARRB1 | Beta-arrestin 1, regulates GPCR desensitization. | Modulates PAFR internalization. |
| ARRB2 | Beta-arrestin 2. | Regulates PAFR signaling and trafficking. |
| GNA11 | G-protein alpha 11. | Couples to PAFR in certain cell types. |
How Is platelet activating factor receptor activity Regulated?
Platelet activating factor receptor activity is regulated at multiple levels. Receptor desensitization and internalization are controlled by phosphorylation and beta-arrestin recruitment. Expression of the PTAFR gene can be modulated by inflammatory stimuli and transcription factors such as NF-kB. Additionally, the availability of PAF, regulated by synthesis and degradation enzymes, influences receptor activation. In disease contexts, PAFR signaling can be amplified or dysregulated, as seen in cancer and inflammatory conditions.
platelet activating factor receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTAFR | Colitis-induced liver inflammation | Knockout mouse model |
| PTAFR | Demyelination | Lysophosphatidylcholine-induced demyelination model |
| PTAFR | Cancer (lung cancer) | Cancer cell lines with PAFR knockout or overexpression |
| PTAFR | Retinal progenitor regulation | Ciliary epithelium cell models |
| PTAFR | Inflammatory diseases | Receptor antagonist studies |
PAFR in Inflammatory Diseases
PAFR signaling is a key driver of inflammation. In a mouse model of colitis, PAFR was shown to limit colitis-induced liver inflammation, suggesting a protective role in this context. PAFR activation leads to production of pro-inflammatory cytokines and chemokines, contributing to tissue damage. Targeting PAFR with antagonists is being explored for inflammatory conditions.
PAFR in Neurological Disorders
PAF and its receptor are implicated in demyelination. In lysophosphatidylcholine-induced demyelination, PAF was found to deteriorate the process via both receptor-dependent and -independent effects. This suggests that PAFR modulation could influence remyelination strategies.
PAFR in Cancer
PAFR signaling promotes cancer progression and therapy resistance. In lung cancer cells, PAFR mediates targeted therapy-induced microvesicle particle release, which may affect tumor microenvironment. Targeting PAF and its receptor is being investigated as a cancer treatment strategy.
PAFR in Retinal Biology
PAFR regulates retinal progenitor/stem cell profile in ciliary epithelium cells, indicating a role in retinal development and potential regenerative medicine. This expands the functional repertoire of PAFR beyond inflammation.
From platelet activating factor receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PAFR mediate colitis-induced liver inflammation? | PTAFR knockout mouse |
| What is the role of PAFR in demyelination? | PTAFR knockout or pharmacological blockade in demyelination models |
| How does PAFR affect cancer microvesicle release? | PTAFR knockout lung cancer cell lines |
| Does PAFR regulate retinal progenitor cells? | PTAFR overexpression or knockout in ciliary epithelium cells |
| What are the structural requirements for PAF binding? | Point mutations in PTAFR ligand-binding domain |
| Can PAFR signaling be modulated by antagonists? | Knock-in models with tagged PAFR and antagonist treatment |
How to Study the platelet activating factor receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of PAFR function | Studying receptor-dependent effects in disease models |
| Calcium mobilization assay | Intracellular calcium flux | Measuring PAFR activation |
| Western blot | Protein expression and phosphorylation | Assessing downstream signaling |
| RNA-seq | Transcriptome changes | Identifying PAFR-regulated genes |
| Reporter assay | NF-kB or other pathway activity | Quantifying inflammatory signaling |
| Microvesicle quantification | Release of microvesicles | Studying PAFR role in cancer therapy response |
| Immunohistochemistry | Tissue localization of PAFR | Analyzing expression in disease tissues |
| Pharmacological blockade | Inhibition of receptor activity | Validating PAFR as therapeutic target |
Genetic Knockout Models
CRISPR-Cas9-mediated knockout of PTAFR in cell lines or animal models allows researchers to study loss-of-function effects on inflammation, cancer, and development. These models help distinguish receptor-dependent from independent effects of PAF.
Pharmacological Tools
PAFR antagonists such as WEB2086 and CV3988 are commonly used to block receptor activity and assess its contribution to disease phenotypes. Combining antagonists with genetic models provides robust evidence.
Signaling Assays
Measurements of intracellular calcium, cAMP, and phosphorylation of downstream effectors (e.g., MAPK, Akt) are used to quantify PAFR activity. Reporter assays for NF-kB activation are also employed.
Expression Analysis
Quantitative PCR, Western blotting, and RNA-seq are used to assess PTAFR expression levels and downstream gene expression changes in response to PAF or receptor modulation.
How CRISPR Can Be Used to Study GO:0004992 platelet activating factor receptor activity
Knockout
CRISPR-Cas9 knockout of PTAFR is used to create isogenic cell lines and animal models to study the loss of PAFR function in inflammation, cancer, and development. These models are essential for distinguishing receptor-specific effects from off-target or receptor-independent actions.
Point Mutation
Introducing point mutations in the PTAFR gene can help identify residues critical for ligand binding, G-protein coupling, or desensitization. Such models are valuable for structure-function studies of the receptor.
Knock-in
Knock-in of tagged PTAFR (e.g., HA or GFP) allows for real-time tracking of receptor localization and trafficking. This approach can also be used to introduce disease-associated mutations or reporter genes.
Overexpression
Overexpression of PTAFR in cell lines can amplify signaling and is used to study gain-of-function effects in cancer and inflammation. It also facilitates biochemical characterization of the receptor.
How EDITGENE Supports platelet activating factor receptor activity Research
Researchers studying platelet activating factor receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional studies of PTAFR and its network.
Contact EDITGENE today to design your custom CRISPR model for platelet activating factor receptor activity research.
Frequently Asked Questions About platelet activating factor receptor activity
What is platelet activating factor receptor activity?
It is a molecular function (GO:0004992) where a receptor binds platelet activating factor (PAF) and initiates a change in cell activity, typically through G-protein-coupled signaling.
What genes are involved in platelet activating factor receptor activity?
The primary gene is PTAFR, which encodes the PAF receptor. Downstream signaling involves G-proteins, phospholipase C, MAPK, and NF-kB pathways.
What diseases are associated with PAFR?
PAFR has been implicated in inflammatory diseases, colitis-induced liver inflammation, demyelination, cancer, and retinal disorders.
How can I study PAFR function?
Common methods include CRISPR knockout, pharmacological antagonists, calcium flux assays, and RNA-seq to assess downstream effects.
Is PAFR a therapeutic target?
Yes, PAFR antagonists are being explored for inflammatory diseases and cancer, and targeting PAFR signaling is an active area of research.
What is the role of PAFR in cancer?
PAFR signaling promotes cancer progression and mediates therapy-induced microvesicle release, making it a potential target for cancer treatment.
Can PAF act independently of its receptor?
Yes, studies in demyelination models show that PAF can exert receptor-independent effects in addition to receptor-mediated actions.
What cell types express PAFR?
PAFR is expressed in various cell types including immune cells, endothelial cells, neurons, and retinal progenitor cells.
How is PAFR signaling regulated?
PAFR is regulated by phosphorylation, beta-arrestin-mediated desensitization, and internalization, as well as by expression levels.
What CRISPR models are available for PAFR research?
Knockout, point mutation, knock-in, and overexpression models can be generated to study PAFR function in vitro and in vivo.
Conclusion
Platelet activating factor receptor activity (GO:0004992) is a fundamental molecular function that mediates the diverse biological actions of PAF. Its role in inflammation, neural development, and cancer underscores its importance as a research focus and therapeutic target. Advances in CRISPR-based genome editing and pharmacological tools continue to unravel the complexities of PAFR signaling, offering new opportunities for disease intervention.
References
- 1. Ishii S et al.. 2002. Platelet-activating factor receptor.. Prostaglandins Other Lipid Mediat 68-69:599-609 PMID: 12432946
- 2. Izumi T et al.. 1995. Platelet-activating factor receptor.. J Lipid Mediat Cell Signal 12(2-3):429-42 PMID: 8777584
- 3. Li XQ et al.. 2018. [Research progress of platelet activating factor(PAF) receptor antagonist].. Zhongguo Zhong Yao Za Zhi 43(7):1392-1403 PMID: 29728028
- 4. Tian Z et al.. 2020. Platelet-Activating Factor Deteriorates Lysophosphatidylcholine-Induced Demyelination Via Its Receptor-Dependent and -Independent Effects.. Mol Neurobiol 57(10):4069-4081 PMID: 32661728
- 5. Liu G et al.. 2020. Platelet activating factor receptor acts to limit colitis-induced liver inflammation.. FASEB J 34(6):7718-7732 PMID: 32293760
- 6. Dalmaso B et al.. 2024. Platelet-Activating Factor Receptor (PAFR) Regulates Retinal Progenitor/Stem Cells Profile in Ciliary Epithelium Cells.. Int J Mol Sci 25(6) PMID: 38542059
- 7. Qaderi K et al.. 2025. Impact of targeting the platelet-activating factor and its receptor in cancer treatment.. Mil Med Res 12(1):10 PMID: 40033370
- 8. Chauhan SJ et al.. 2020. Platelet-Activating Factor-Receptor Signaling Mediates Targeted Therapies-Induced Microvesicle Particles Release in Lung Cancer Cells.. Int J Mol Sci 21(22) PMID: 33198218
